A new study presented at the American Society of Clinical Oncology (ASCO) annual meeting showed that Belzutifan treatment of VHL-related tumors durably shrinks tumors and may reduce the number of surgeries needed in patients with cancers associated with a von Hippel-Lindau (VHL) gene deletion or mutation.
Five-year follow-up findings showed the following response rates:
- Renal cell cancer: 70%
- Hemangioblastomas of the CNS: 50%
- Pancreatic neuroendocrine tumors (PNET): 90%
Learn more by reading the Renal & Urology News article: https://www.renalandurologynews.com/reports/cancer-belzutifan-durable-response-von-hippel-lindau-treatment-risk/
Reference: Sakhnovsky. Renal & Urology News. Belzutifan Provides Durable Response in Von Hippel Lindau-Related Cancers Such as RCC.
